Open-label, follow-up study for subjects who completed the EPITOPE study.
Age: 2 - 5 years
Gender: All
We've found 4 total result s for "Peanut Hypersensitivity".
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
Age: 1 year - 55 years
Gender: All
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.
Age: 4 - 55 years
Gender: All
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.
Age: 5 - 50 years
Gender: All